Foster City, CA, United States of America

Jeffrey T Finer

This inventor holds 35 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Quinazolinone Compositions. Top assignees: Cytokinetics, Inc., Five Prime Therapeutics, Inc.. Active years: 2002-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey T Finer. Retrieved from https://idiyas.com/inventor/jeffrey-t-finer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 35 (Patent Applications = 3)

% Patents Active = 54.3

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.5

ph-index = 11

Forward Citations = 533(Granted Patents)

Company Filing History:

Five Prime Therapeutics, Inc.

patents

Years Active: 2002-2014

Loading Chart...

Areas of Expertise:

Quinazolinone

Kinesin Inhibitors

Protein Modulators

ADP Detection

Phosphate Detection

Sarcomere Assays

Heart Failure Treatment

Nucleic Acids

Chemical Entities

High Sensitivity Assays

Actin Purification

Cell Proliferation

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8658656 - Methods and compositions utilizing quinazolinones (2014-02-25),

2. 8470838 - Methods and compositions utilizing quinazolinones (2013-06-25),

3. 8324165 - Compositions for treating arthritis comprising HG1023575 polypeptide (2012-12-04),

4. 8293761 - Certain chemical entities, compositions and methods (2012-10-23),

5. 8063082 - Certain chemical entities, compositions, and methods (2011-11-22),

6. 8008311 - Methods and compostions utilizing quinazolinones (2011-08-30),

7. 7956056 - Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use (2011-06-07),

8. 7932270 - Certain chemical entities, compositions, and methods (2011-04-26),

9. 7919511 - Certain chemical entities, compositions, and methods (2011-04-05),

10. 7824880 - High sensitivity assay for detection of nucleoside diphosphate production (2010-11-02),

11. 7763628 - Methods and compositions utilizing quinazolinones (2010-07-27),

12. 7671200 - Quinazolinone KSP inhibitors (2010-03-02),

13. 7598248 - Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols, compositions thereof, and methods for their use (2009-10-06),

14. 7589098 - Methods and compositions utilizing quinazolinones (2009-09-15),

15. 7416856 - High sensitivity assay for detection of nucleoside diphosphate production (2008-08-26),

Title: Spotlight on Inventor Jeffrey T Finer: Pioneering Innovations in Foster City, CA

Introduction:

In the realm of cellular proliferative disease treatments and KSP kinesin activity, few inventors shine as brightly as Jeffrey T Finer, whose groundbreaking work has led to 35 patents and counting. Hailing from Foster City, CA, Finer is a distinguished inventor with a passion for pushing the boundaries of medical science.

Latest Patents:

Among his latest patents are innovative methods and compositions utilizing quinazolinones. Formulated with precision and expertise, these compounds (formulae 1a, 1b, 1c, and 1d) demonstrate tremendous efficacy in combating cellular proliferative diseases and disorders associated with KSP kinesin activity. Finer's relentless pursuit of excellence is evident in each patent he produces.

Career Highlights:

Throughout his illustrious career, Jeffrey T Finer has made significant contributions to renowned companies such as Cytokinetics, Inc. and Five Prime Therapeutics, Inc. His expertise and dedication have paved the way for cutting-edge advancements in the field of biomedical research, solidifying his reputation as a trailblazer in the industry.

Collaborations:

Collaboration lies at the heart of innovation, and Jeffrey T Finer has had the privilege of working alongside esteemed colleagues like John Clifford Chabala and Roman Sakowicz. Together, they have tackled complex challenges, shared knowledge, and fostered a culture of creativity that continues to drive progress in the field.

Conclusion:

Inventor Jeffrey T Finer's indelible mark on the world of biomedical research is a testament to his unwavering commitment to innovation. Through his pioneering spirit, relentless work ethic, and passion for discovery, Finer has not only transformed the landscape of cellular proliferative disease treatments but has also inspired future generations of inventors to push the boundaries of what is possible in the realm of medical science.

Profile summary based on public USPTO records.